Proof that Amgen is short of molecules, just like the rest of Big Pharma.
Predix Pharmaceuticals said it has signed a licensing agreement with Amgen for its autoimmune disease treatment worth over $307 million.
Under the terms of the agreement, the company said Amgen will pay an initial $20 mln for the license and up to an additional $287.5 mln in milestone payments if certain clinical, regulatory and sales milestones are achieved.
No comments:
Post a Comment